Nitec Pharma AG, of Basel, Switzerland, appointed Stephen Witte chief medical officer and head of global clinical development; Michael Luttgen vice president of marketing and sales; Hans Rensland vice president of regulatory affairs; Rainer Rogasch vice president of technical operations and development; Markus Vogt vice president of quality and compliance; and James Audibert vice president of commercial optimization.

Northwest Biotherapeutics Inc., of Bethesda, Md., appointed Anthony Deasey senior vice president of finance, chief financial officer and board member.

Novelos Therapeutics Inc., of Newton, Mass., elected Stephen Hill nonexecutive chairman.

Nventa Biopharmaceuticals Corp., of San Diego, added Mark Einstein, Warner Huh and Richard Ulevitch to its clinical and scientific advisory board.

Onyx Pharmaceuticals Inc., of Emeryville, Calif., promoted Laura Brege to executive vice president and chief operating officer and Randy Kelley to senior vice president of sales and marketing.

Opexa Therapeutics Inc., of The Woodlands, Texas, named Lorin Jeffry Randall to its board. It also named Dawn McGuire to its clinical advisory board for multiple sclerosis.

OPKO Health Inc., of Miami, appointed Pascal Goldschmidt to its board.

Othera Pharmaceuticals Inc., of Exton, Pa., appointed Frederick Rickles chief scientific officer.

Oxford Bioscience Partners, of Boston, promoted Douglas Fambrough to general partner.

Paramount BioSciences, of New York, appointed Robert Jacks vice president of business development.

Peptimmune Inc., of Cambridge, Mass., appointed Fredric Price executive chairman.

Pharmacyclics Inc., of Sunnyvale, Calif., appointed Robert Duggan to its board.